Preferential Issue of 46,43,000 convertible equity warrants to promoter subject to approval from shareholders.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Shukra Pharmaceuticals has approved issuing 46,43,000 convertible equity warrants to promoter group shareholders at Rs. 34 per warrant, raising up to Rs. 15.79 crores in total. Each warrant can be converted into one equity share, with buyers paying 25% upfront and the remaining 75% at the time of conversion. The warrants have an 18-month exercise window, after which unexercised warrants will lapse and the upfront amount will be forfeited. An extraordinary general meeting has been scheduled for November 01, 2025 to seek shareholder approval for the issue.
This is a promoter-led capital infusion, which signals promoter confidence in the company but will result in dilution of existing public shareholders once warrants are exercised. Shareholders should watch for the EGM outcome on November 01, 2025, as their approval is required for the issue to proceed.